FDA Approves Digital Pill

FDA Approves Digital Pill

FDA Approves Digital Pill

That app can then track how often the patient takes a pill and whether they've missed any doses.

The FDA says that the ability to track the consumption of prescribed medicines for mental illness may be useful "for some patients", although the ability of digital pills to improve patient compliance has not been proven.

In prescribing Abilify MyCite, physicians must make sure patients download the corresponding mobile application on their smartphones and are comfortable using it, since that is how they will ultimately view the information provided from the drug-device combo.

Abilify MyCite's approval was granted to Japan's Otsuka Pharmaceuticals.

Schizophrenia is a chronic, severe, and disabling brain disorder.

Aripiprazole is used to treat multiple mental mood disorders, including bipolar disorder and schizophrenia.

Wait over for same sex marriage survey result
Australia is learning whether the public supports same sex marriage , as the results come back from their non-binding vote. When interviewed, Paterson said his bill would give people the right to "conscientiously object and not participate".

Abilify MyCite is not approved for patients with dementia-related psychosis; it has a Boxed Warning that taking this medication puts patients with dementia-related psychosis at an increased risk of death.

The FDA approval for Abilify MyCite's pill could lead the way for other electronic pills to become available that'll be able to treat other health issues.

What are some potentially risky risks of Abilify MyCite? Additionally, the medication has been associated with increased suicidal thoughts and behavior in children, adolescents, and young adults taking antidepressants. The safety and effectiveness of Abilify MyCite have not been established in pediatric patients. The atypical antipsychotic drug is already available as a cheap generic, and doctors are already using an injectable, long-lasting version-Abilify Maintena-to manage patients who have problems sticking to a daily pill regimen. The sensor in Ability MyCite syncs with a smart phone and sends an alert when the medication is ingested via a patch that is worn on the surface of the skin.

In clinical trials establishing the efficacy of aripiprazole, the most common adverse events were nausea, vomiting, constipation, headache, dizziness, uncontrollable limb and body movements (akathisia), anxiety, insomnia, and restlessness.

The sensor technology and patch are made by Proteus Digital Health, and are approved for use with existing medications in the United States and Europe. This first US approval could bode well for other new products in the works, including sensor-embedded versions of generic blood pressure pill lisinopril and the standard diabetes drug metformin.

Related news